Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS (ZBH)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Zimmer Holdings, Inc. : Zimmer Receives FDA Warning on Certain Hip Implants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2012 | 12:40am CET

--Zimmer says FDA inspection of Puerto Rico plant turned up concerns about manufacturing of certain implants

--FDA in letter noted manufacturing, testing issues related to Trilogy Acetabuar System products, company says

--Zimmer says it is notifying customers of manufacturing issue, but hasn't withdrawn any products

(Adds context on metallic spikes in fourth paragraph and a no comment from Zimmer in seventh paragraph.)

 
   By Kristin Jones 
 

Zimmer Holdings Inc. (ZMH) said a U.S. Food and Drug Administration inspection of its plant in Puerto Rico turned up concerns about the manufacturing of certain hip implants.

The orthopedic maker's Zimmer Inc. subsidiary received a warning letter from the FDA dated Sept. 19, the company said in a regulatory filing Monday. In the letter, the FDA noted manufacturing and testing issues related to the company's Trilogy Acetabular System products, which are implanted in hip-replacement surgery.

Specifically, the U.S. drug regulator noted that Zimmer hadn't implemented a testing mechanism to show that its products met design specifications. The company also hadn't validated the effect of certain manufacturing operations on Trilogy products that incorporate metallic spikes.

Spikes are used to connect the hip replacement cup to a patient's bone when cement and screws are deemed insufficient.

The FDA requires that drug and medical-device makers undertake steps to ensure the quality of the design and manufacture of its products, known as process validation.

Zimmer said it is notifying customers of the manufacturing issue, but that it hasn't withdrawn any products. The company also said it previously suspended release of the spiked products, pending validation of the processes cited in the letter, and expects to complete validation in the next few weeks.

A Zimmer spokesman declined to comment further.

Shares gained 11 cents to $67.98 in after-hours trading. Through Monday's close, the stock was up 27% so far this year.

--Joseph Walker contributed to this article.

Write to Kristin Jones at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Valeurs citées dans l'article
ChangeLast1st jan.
ZIMMER BIOMET HOLDINGS 0.33% 118.985 Delayed Quote.-1.62%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS
02/20ZIMMER BIOMET : Sponsors Bike Share Program for Warsaw Community
PU
02/15ZIMMER BIOMET : Rapid Recovery Program Marks Two Decades of Success in Europe
AQ
02/14INSIDER TRADING ACTIVITY ZIMMER BIOM : ZBH) – VP Sold 20,826 shares of Sto..
AQ
02/14MEDICAL SPLINT MARKET ANALYSIS, SEGM : Medical Splint Market Overview & Industry..
AQ
02/12ZIMMER BIOMET : Rapid Recovery Program Marks Two Decades of Success in Europe
AQ
02/08ZIMMER BIOMET : Rapid Recovery Program Marks Two Decades of Success in Europe
PR
02/01ZIMMER BIOMET : Comprehensive Shoulder System Database Retrieval
AQ
02/01ZIMMER BIOMET : Announces Fourth Quarter and Full-Year 2017 Results
AQ
02/01SPINAL FUSION SYSTEMS MARKET ANALYSI : Spinal Fusion Systems Market Overview & I..
AQ
01/30ZIMMER BIOMET (NYSE : ZBH) reported earnings of $2.10 per share meeting Walls St..
AQ
More news
News from SeekingAlpha
02/05PRECISION THERAPEUTICS : An Unloved Medical Device Company With Significant Upsi.. 
01/31Stryker Producing Excellent Results, But Expectations Are High 
01/31Premarket analyst action - healthcare 
01/30Zimmer Biomet's (ZBH) CEO Bryan Hanson on Q4 2017 Results - Earnings Call Tra.. 
01/30Zimmer Biomet Q4 revenues up 3%; non-GAAP EPS down 2%; updates guidance 
Financials ($)
Sales 2018 7 959 M
EBIT 2018 2 322 M
Net income 2018 1 080 M
Debt 2018 7 962 M
Yield 2018 0,85%
P/E ratio 2018 25,13
P/E ratio 2019 20,69
EV / Sales 2018 4,02x
EV / Sales 2019 3,77x
Capitalization 24 030 M
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 141 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Bryan C. Hanson President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Adrian Furey Senior VP-Global Operations & Logistics
Daniel P. Florin Chief Financial Officer & Director
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS-1.62%24 030
MEDTRONIC PLC1.07%109 254
BAXTER INTERNATIONAL3.71%36 531
ALIGN TECHNOLOGY14.97%20 216
HOYA CORPORATION-3.59%19 635
TERUMO CORP2.60%19 495